Omnicell, Inc. (OMCL)
NASDAQ: OMCL · Real-Time Price · USD
31.35
-0.19 (-0.60%)
Aug 13, 2025, 4:00 PM - Market closed
Omnicell Revenue
Omnicell had revenue of $290.56M in the quarter ending June 30, 2025, with 4.98% growth. This brings the company's revenue in the last twelve months to $1.15B, up 6.39% year-over-year. In the year 2024, Omnicell had annual revenue of $1.11B, down -3.04%.
Revenue (ttm)
$1.15B
Revenue Growth
+6.39%
P/S Ratio
1.27
Revenue / Employee
$313,223
Employees
3,670
Market Cap
1.44B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.11B | -34.87M | -3.04% |
Dec 31, 2023 | 1.15B | -148.84M | -11.48% |
Dec 31, 2022 | 1.30B | 163.93M | 14.48% |
Dec 31, 2021 | 1.13B | 239.81M | 26.88% |
Dec 31, 2020 | 892.21M | -4.82M | -0.54% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
OMCL News
- 12 days ago - Omnicell, Inc. (OMCL) Q2 2025 Earnings Conference Call Transcript - Seeking Alpha
- 13 days ago - Omnicell Q2 Earnings: Market Ignoring The Segments - Seeking Alpha
- 14 days ago - Omnicell Announces Second Quarter 2025 Results - Business Wire
- 4 weeks ago - Omnicell to Release Second Quarter 2025 Financial Results on July 31, 2025 - Business Wire
- 3 months ago - Omnicell Expects Improved Profitability, Updates Second Quarter and Full Year 2025 Profit Outlook and Announces a New Stock Repurchase Program - Business Wire
- 3 months ago - Omnicell Announces New Products for Perioperative and Clinic Settings - Business Wire
- 3 months ago - Omnicell Opens New Innovation Lab in Austin, Texas - Business Wire
- 3 months ago - Omnicell: Facing New Headwinds - Seeking Alpha